Want to see NUVL full AI Analyst Report?
NUVL Stock Chart & Stats
$107.61
-$0.36(-0.45%)
At close: 4:00 PM EST
$107.61
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume65.93K
Average Volume (3M)N/A
Market Cap
$9.79B
Enterprise Value$6.77K
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 06, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.06
Shares Outstanding73,562,660
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$125.26Price Target Upside16.40% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-5.75
Revenue Forecast (FY)$9.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and roughly $1.17B of equity give the company durable financial flexibility to fund clinical programs and negotiations. Low leverage reduces refinancing risk, supports R&D spending cadence, and provides a buffer versus short-term funding shocks over the next several months.
Acquisition Agreement With GSKA signed merger agreement with GSK is a structural change that materially de-risks financing and commercialization paths: it brings large pharma capabilities, committed deal mechanics (tender/support agreements, no-financing contingency) and accelerates the route to market for late-stage assets.
Regulatory Milestone: NDA FilingAn FDA New Drug Application for neladalkib is a substantive, lasting development milestone that moves the lead program from trials to regulatory review. This increases the probability of near-term commercialization or deal value realization and strengthens long-term franchise prospects if approved.
Bears Say
Pre-revenue With Widening LossesBeing pre-revenue while incurring rapidly expanding R&D and operating losses creates a persistent profitability gap. Without product sales, the company depends on milestone outcomes or transaction execution to justify capital deployment and restore earnings potential over the medium term.
Accelerating Cash BurnDeeply negative free cash flow and accelerating burn imply ongoing reliance on external capital unless commercialization or a closing transaction occurs. Even with a strong balance sheet, sustained negative cash generation constrains optionality and increases execution risk over the next several quarters.
Concentrated, Late-stage Asset RiskThe business outcome hinges on a small number of late-stage candidates (ROS1, ALK). This concentration makes long-term prospects binary: regulatory setbacks, competition, or safety issues with one or both leads would materially harm future revenue potential and limit diversification.
Nuvalent News
NUVL FAQ
What was Nuvalent, Inc. Class A’s price range in the past 12 months?
Currently, no data Available
What is Nuvalent, Inc. Class A’s market cap?
Nuvalent, Inc. Class A’s market cap is $9.79B.
When is Nuvalent, Inc. Class A’s upcoming earnings report date?
Nuvalent, Inc. Class A’s upcoming earnings report date is Aug 06, 2026 which is in 16 days.
How were Nuvalent, Inc. Class A’s earnings last quarter?
Nuvalent, Inc. Class A released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.05.
Is Nuvalent, Inc. Class A overvalued?
According to Wall Street analysts Nuvalent, Inc. Class A’s price is currently Undervalued.
Does Nuvalent, Inc. Class A pay dividends?
Nuvalent, Inc. Class A does not currently pay dividends.
What is Nuvalent, Inc. Class A’s EPS estimate?
Nuvalent, Inc. Class A’s EPS estimate is -1.41.
How many shares outstanding does Nuvalent, Inc. Class A have?
Nuvalent, Inc. Class A has 73,562,660 shares outstanding.
What happened to Nuvalent, Inc. Class A’s price movement after its last earnings report?
Nuvalent, Inc. Class A reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -1.784%.
Which hedge fund is a major shareholder of Nuvalent, Inc. Class A?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$125.26 (16.40% Upside)
$125.26 (16.40% Upside)
Hedge Fund Trend
Decreased
By 310.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.38%
Trailing 12-Months
NUVL Stock 12 Month Forecast
Average Price Target
$125.26
▲(16.40% Upside)
Technical Analysis
Ownership Overview
3.20% Insiders
31.41% Mutual Funds
0.23% Other Institutional Investors
58.33% Public Companies and
Individual Investors